vs
Side-by-side financial comparison of Teledyne Technologies (TDY) and Zoetis (ZTS). Click either name above to swap in a different company.
Zoetis is the larger business by last-quarter revenue ($2.4B vs $1.6B, roughly 1.5× Teledyne Technologies). Zoetis runs the higher net margin — 25.3% vs 17.1%, a 8.2% gap on every dollar of revenue. On growth, Teledyne Technologies posted the faster year-over-year revenue change (7.3% vs 3.0%). Zoetis produced more free cash flow last quarter ($732.0M vs $339.2M). Over the past eight quarters, Teledyne Technologies's revenue compounded faster (9.3% CAGR vs 4.4%).
Teledyne Technologies Incorporated is an American industrial conglomerate. It was founded in 1960, as Teledyne, Inc. by Henry Singleton and George Kozmetsky.
Zoetis Inc. (/zō-EH-tis/) is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. The company directly markets its products in approximately 45 countries, and sells them in more than 100 countries. Operations outside the United States accounted for 50% of the total re...
TDY vs ZTS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.6B | $2.4B |
| Net Profit | $275.6M | $603.0M |
| Gross Margin | 42.9% | 70.2% |
| Operating Margin | 20.4% | 31.9% |
| Net Margin | 17.1% | 25.3% |
| Revenue YoY | 7.3% | 3.0% |
| Net Profit YoY | 38.8% | 3.8% |
| EPS (diluted) | $5.81 | $1.37 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.6B | $2.4B | ||
| Q3 25 | $1.5B | $2.4B | ||
| Q2 25 | $1.5B | $2.5B | ||
| Q1 25 | $1.4B | $2.2B | ||
| Q4 24 | $1.5B | $2.3B | ||
| Q3 24 | $1.4B | $2.4B | ||
| Q2 24 | $1.4B | $2.4B | ||
| Q1 24 | $1.4B | $2.2B |
| Q4 25 | $275.6M | $603.0M | ||
| Q3 25 | $220.7M | $721.0M | ||
| Q2 25 | $209.9M | $718.0M | ||
| Q1 25 | $188.6M | $631.0M | ||
| Q4 24 | $198.5M | $581.0M | ||
| Q3 24 | $262.0M | $682.0M | ||
| Q2 24 | $180.2M | $624.0M | ||
| Q1 24 | $178.5M | $599.0M |
| Q4 25 | 42.9% | 70.2% | ||
| Q3 25 | 42.8% | 71.5% | ||
| Q2 25 | 42.6% | 73.6% | ||
| Q1 25 | 42.7% | 72.0% | ||
| Q4 24 | 42.8% | 69.5% | ||
| Q3 24 | 42.9% | 70.6% | ||
| Q2 24 | 43.1% | 71.7% | ||
| Q1 24 | 43.0% | 70.6% |
| Q4 25 | 20.4% | 31.9% | ||
| Q3 25 | 18.4% | 37.0% | ||
| Q2 25 | 18.4% | 36.7% | ||
| Q1 25 | 17.9% | 36.5% | ||
| Q4 24 | 15.8% | 31.6% | ||
| Q3 24 | 18.8% | 36.6% | ||
| Q2 24 | 18.0% | 33.0% | ||
| Q1 24 | 17.4% | 34.1% |
| Q4 25 | 17.1% | 25.3% | ||
| Q3 25 | 14.3% | 30.0% | ||
| Q2 25 | 13.9% | 29.2% | ||
| Q1 25 | 13.0% | 28.4% | ||
| Q4 24 | 13.2% | 25.1% | ||
| Q3 24 | 18.2% | 28.6% | ||
| Q2 24 | 13.1% | 26.4% | ||
| Q1 24 | 13.2% | 27.4% |
| Q4 25 | $5.81 | $1.37 | ||
| Q3 25 | $4.65 | $1.63 | ||
| Q2 25 | $4.43 | $1.61 | ||
| Q1 25 | $3.99 | $1.41 | ||
| Q4 24 | $4.18 | $1.29 | ||
| Q3 24 | $5.54 | $1.50 | ||
| Q2 24 | $3.77 | $1.37 | ||
| Q1 24 | $3.72 | $1.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $352.4M | — |
| Total DebtLower is stronger | $2.5B | — |
| Stockholders' EquityBook value | $10.5B | $3.3B |
| Total Assets | $15.3B | $15.5B |
| Debt / EquityLower = less leverage | 0.24× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $352.4M | — | ||
| Q3 25 | $528.6M | $2.1B | ||
| Q2 25 | $310.9M | $1.4B | ||
| Q1 25 | $461.5M | $1.7B | ||
| Q4 24 | $649.8M | $2.0B | ||
| Q3 24 | $561.0M | $1.7B | ||
| Q2 24 | $443.2M | $1.6B | ||
| Q1 24 | $912.4M | $2.0B |
| Q4 25 | $2.5B | — | ||
| Q3 25 | $2.5B | — | ||
| Q2 25 | $2.6B | — | ||
| Q1 25 | $3.0B | — | ||
| Q4 24 | $2.6B | — | ||
| Q3 24 | $2.8B | — | ||
| Q2 24 | $2.8B | — | ||
| Q1 24 | $3.2B | — |
| Q4 25 | $10.5B | $3.3B | ||
| Q3 25 | $10.6B | $5.4B | ||
| Q2 25 | $10.4B | $5.0B | ||
| Q1 25 | $9.9B | $4.7B | ||
| Q4 24 | $9.5B | $4.8B | ||
| Q3 24 | $9.6B | $5.2B | ||
| Q2 24 | $9.3B | $5.0B | ||
| Q1 24 | $9.3B | $5.1B |
| Q4 25 | $15.3B | $15.5B | ||
| Q3 25 | $15.4B | $15.2B | ||
| Q2 25 | $15.1B | $14.5B | ||
| Q1 25 | $15.0B | $14.1B | ||
| Q4 24 | $14.2B | $14.2B | ||
| Q3 24 | $14.5B | $14.4B | ||
| Q2 24 | $14.2B | $14.2B | ||
| Q1 24 | $14.6B | $14.3B |
| Q4 25 | 0.24× | — | ||
| Q3 25 | 0.24× | — | ||
| Q2 25 | 0.25× | — | ||
| Q1 25 | 0.30× | — | ||
| Q4 24 | 0.28× | — | ||
| Q3 24 | 0.29× | — | ||
| Q2 24 | 0.30× | — | ||
| Q1 24 | 0.35× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $379.0M | $893.0M |
| Free Cash FlowOCF − Capex | $339.2M | $732.0M |
| FCF MarginFCF / Revenue | 21.0% | 30.7% |
| Capex IntensityCapex / Revenue | 2.5% | 6.7% |
| Cash ConversionOCF / Net Profit | 1.38× | 1.48× |
| TTM Free Cash FlowTrailing 4 quarters | $1.1B | $2.3B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $379.0M | $893.0M | ||
| Q3 25 | $343.1M | $938.0M | ||
| Q2 25 | $226.6M | $486.0M | ||
| Q1 25 | $242.6M | $587.0M | ||
| Q4 24 | $332.4M | $905.0M | ||
| Q3 24 | $249.8M | $951.0M | ||
| Q2 24 | $318.7M | $502.0M | ||
| Q1 24 | $291.0M | $595.0M |
| Q4 25 | $339.2M | $732.0M | ||
| Q3 25 | $313.9M | $805.0M | ||
| Q2 25 | $196.3M | $308.0M | ||
| Q1 25 | $224.6M | $438.0M | ||
| Q4 24 | $303.4M | $689.0M | ||
| Q3 24 | $228.7M | $784.0M | ||
| Q2 24 | $301.0M | $370.0M | ||
| Q1 24 | $275.1M | $455.0M |
| Q4 25 | 21.0% | 30.7% | ||
| Q3 25 | 20.4% | 33.5% | ||
| Q2 25 | 13.0% | 12.5% | ||
| Q1 25 | 15.5% | 19.7% | ||
| Q4 24 | 20.2% | 29.7% | ||
| Q3 24 | 15.8% | 32.8% | ||
| Q2 24 | 21.9% | 15.7% | ||
| Q1 24 | 20.4% | 20.8% |
| Q4 25 | 2.5% | 6.7% | ||
| Q3 25 | 1.9% | 5.5% | ||
| Q2 25 | 2.0% | 7.2% | ||
| Q1 25 | 1.2% | 6.7% | ||
| Q4 24 | 1.9% | 9.3% | ||
| Q3 24 | 1.5% | 7.0% | ||
| Q2 24 | 1.3% | 5.6% | ||
| Q1 24 | 1.2% | 6.4% |
| Q4 25 | 1.38× | 1.48× | ||
| Q3 25 | 1.55× | 1.30× | ||
| Q2 25 | 1.08× | 0.68× | ||
| Q1 25 | 1.29× | 0.93× | ||
| Q4 24 | 1.67× | 1.56× | ||
| Q3 24 | 0.95× | 1.39× | ||
| Q2 24 | 1.77× | 0.80× | ||
| Q1 24 | 1.63× | 0.99× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
TDY
| Commercial And Other | $681.5M | 42% |
| Aerospace And Defense Electronics | $275.9M | 17% |
| Marine Instrumentation | $177.1M | 11% |
| United States Government | $169.0M | 10% |
| Environmental Instrumentation | $120.7M | 7% |
| Engineered Systems | $103.3M | 6% |
| Test And Measurement Instrumentation | $84.8M | 5% |
ZTS
| Other | $1.3B | 56% |
| Livestock | $234.0M | 10% |
| Pain Sedation | $209.0M | 9% |
| Other Pharmaceuticals | $188.0M | 8% |
| Swine | $125.0M | 5% |
| Poultry | $117.0M | 5% |
| Fish | $81.0M | 3% |
| Other Non Pharmaceuticals | $70.0M | 3% |
| Manufactured Product Other | $18.0M | 1% |
| Medicated Feed Additives | $12.0M | 1% |
